/compare — side-by-sideLOADING
Valuation, growth, margins and forensic scores side-by-side — computed from each company's own SEC filings and last EOD close. No estimates, no fluff.
| Metric | LEXXLexaria Bioscience C |
|---|---|
| Last close | $4.54close 2026-11-09 |
| Change % | +0.89%close 2026-11-09 |
| Market cap | $113Mclose 2026-11-09 |
| P/E | loss, no P/E |
| Revenue | $705923⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldRevenues As ofFY ending 2025-08-31 |
Fundamentals from XBRL company facts (as filed); market cap & P/E use last EOD close. Each cell names its period. A ratio row reads not comparable when the companies’ periods differ by more than six weeks or mix a fiscal year with a trailing twelve months, and a figure more than a year older than the company’s newest period is marked older period. No row ranks the companies. Educational only, not investment advice.
| Rev growth (YoY) | 52.0%FY to 2025-08-31 |
| Net income | $-11901841⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldNetIncomeLoss As ofFY ending 2025-08-31 Filing10-K · 0001640334-25-002225 · filed 2025-11-28 Open the filing on EDGAR →Open the XBRL payload →CiteLexaria Bioscience Corp. (LEXX), us-gaap:NetIncomeLoss: -11,901,841 USD, fiscal year ended 2025-08-31. Form 10-K, accession 0001640334-25-002225, filed 2025-11-28. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0001348362/us-gaap/NetIncomeLoss.json |
| Net margin | -1686.0%FY to 2025-08-31 |
| EPS (diluted) | $-0.66⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldEarningsPerShareDiluted As ofFY ending 2025-08-31 Filing10-K · 0001640334-25-002225 · filed 2025-11-28 Open the filing on EDGAR →Open the XBRL payload →CiteLexaria Bioscience Corp. (LEXX), us-gaap:EarningsPerShareDiluted: -0.66 USD per share, fiscal year ended 2025-08-31. Form 10-K, accession 0001640334-25-002225, filed 2025-11-28. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0001348362/us-gaap/EarningsPerShareDiluted.json |
| Piotroski F-ScoreUNVALIDATED | 4FY to 2025-08-31 |
| Altman Z-ScoreUNVALIDATED | 13.01FY to 2025-08-31 |
| Beneish M-ScoreUNVALIDATED | inputs not filed |
| Next earnings | — |